ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Peter A. Thompson sold 83,695 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $13.00, for a total transaction of $1,088,035.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.
ARS Pharmaceuticals Price Performance
Shares of SPRY stock traded down $0.22 during mid-day trading on Wednesday, hitting $13.74. The company had a trading volume of 980,976 shares, compared to its average volume of 720,059. The stock’s 50 day moving average price is $10.64 and its 200-day moving average price is $9.46. ARS Pharmaceuticals, Inc. has a 52-week low of $2.55 and a 52-week high of $16.50. The company has a market capitalization of $1.33 billion, a P/E ratio of -26.54 and a beta of 0.87.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $2.00 million. On average, equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on SPRY
Institutional Investors Weigh In On ARS Pharmaceuticals
Large investors have recently bought and sold shares of the business. RA Capital Management L.P. grew its holdings in shares of ARS Pharmaceuticals by 14.8% in the first quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company’s stock worth $110,999,000 after purchasing an additional 1,401,299 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of ARS Pharmaceuticals by 37.0% in the first quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company’s stock worth $29,500,000 after purchasing an additional 779,969 shares during the last quarter. ClariVest Asset Management LLC bought a new position in shares of ARS Pharmaceuticals in the first quarter worth about $2,790,000. Jacobs Levy Equity Management Inc. grew its holdings in shares of ARS Pharmaceuticals by 1,280.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 277,706 shares of the company’s stock worth $2,838,000 after purchasing an additional 257,589 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of ARS Pharmaceuticals by 5.9% in the fourth quarter. Franklin Resources Inc. now owns 4,098,497 shares of the company’s stock worth $22,460,000 after purchasing an additional 229,988 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
See Also
- Five stocks we like better than ARS Pharmaceuticals
- What is a Secondary Public Offering? What Investors Need to Know
- BHP Stock: The Under-the-Radar Growth Story in Commodities
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Analysts Upgrade These 3 Hot Buy-and-Hold Stocks
- What is a support level?
- Kohl’s Charts a Resilient Path in a Challenging Retail Landscape
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.